The Pfizer Clinical Research Unit in New Haven is conducting a clinical trial of a study drug for migraines. This study will compare the effects of two different formulations of the study drug when given to healthy adults without food.
Migraine is a debilitating disorder that causes moderate to severe throbbing pain or a pulsing sensation that affects 15% of all adults. A person with migraine often also has nausea, vomiting, and sensitivity to light and sound. These symptoms can last for hours to days and the pain can be so bad that it interferes with daily activities. Despite advances in migraine management, there is still a critical need for treatments for patients of all ages that continue to experience migraines.
Learn how you can help patients as a healthy volunteer below.
Who may participate
We understand that participation in medical research is an important but personal choice, and we are grateful for every person that chooses to join one of our trials.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. Healthy volunteers are a vital part of medical discovery and help build the foundations for further research.
In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18+ years
Sex
All
Referral bonus
Up to $150
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 20 consecutive overnights*. Starting the morning after you arrive, you will receive a single oral dose of the study drug up to 4 separate times, with about 5 days between each dose. Each dose will be given after an overnight fast and will either be a tablet that you will swallow whole or a tablet that you will dissolve on top of your tongue. Both types of tablets contain the same amount of the study drug.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
*If you are selected for dosing, you will need to remain at the PCRU for this entire duration for observation unless you choose to withdraw from the study.
Required overnight stays
20 consecutive nights*
Long-term follow up
1 phone call
How long is this study?
About 45 days
Compensation
Up to $9,100 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
We've updated the PCRU Loyalty Program!
We refreshed our Participant Loyalty Program with all-new unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.